Weight-based oxytocin infusion for preventing uterine atony during caesarean delivery in non-labouring patients: A dose-response study

Clin Exp Pharmacol Physiol. 2023 Jun;50(6):497-503. doi: 10.1111/1440-1681.13766. Epub 2023 Mar 8.

Abstract

Postpartum haemorrhage remains a significant cause of maternal morbidity and mortality with the commonest reason being uterine atony. For prevention of uterine atony during caesarean delivery, oxytocin is advocated as a first line drug. There is however no published data regarding utility of a weight-based oxytocin infusion. The present study evaluated dose-response relationship for oxytocin infusion when used as weight-based regimen. A total of 55 non-labouring patients without risk factors for uterine atony and scheduled for caesarean delivery under spinal anaesthesia were enrolled. Randomization was done to receive oxytocin infusion in a dose of 0.1, 0.15, 0.2, 0.25 or 0.3 IU kg-1 h-1 (n = 11 each), initiated at the time of cord clamping and continued until the end of surgery. Successful outcome was defined as attaining an adequate uterine response at 4 min of initiation of infusion and maintained till end of surgery. Oxytocin associated hypotension, tachycardia, ST-T changes, nausea/vomiting, flushing and chest pain were also observed. A significant linear trend for adequate intraoperative uterine tone was seen with increasing dose of weight-based oxytocin infusion (P < 0.001). The effective dose in 90% population (ED90) was 0.29 IU kg-1 h-1 (95% CI = 0.25-0.42). Amongst the oxytocin associated side effects, a significant linear trend was seen between increasing dose of oxytocin infusion and hypotension as well as nausea/vomiting (p = 0.016 and 0.023 respectively). Thus, oxytocin infusion during caesarean delivery may be used as per the patient's body weight.

Keywords: cesarean delivery; minimum effective dose; oxytocin; uterine tone; weight-based dose.

MeSH terms

  • Cesarean Section / adverse effects
  • Female
  • Humans
  • Hypotension* / drug therapy
  • Oxytocics* / adverse effects
  • Oxytocin
  • Pregnancy
  • Uterine Inertia* / drug therapy
  • Uterine Inertia* / etiology
  • Uterine Inertia* / prevention & control

Substances

  • Oxytocin
  • Oxytocics